相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1951
已完成
1
20.0%
尚未招募
1
20.0%
招募中
1
20.0%
Unknown
2
40.0%
暂无批准数据
- Professor Robyn Jamieson's team received $200,000 from the NSW Government's NAT-Net scheme to advance lab-grown retina research for inherited blindness over two years. - The project uses non-animal technologies to identify which patients with inherited blindness are most likely to respond to gene therapy, enabling access to previously unavailable treatments. - Two additional grants were awarded for programmable microbeads to grow human tissue and a computer model predicting side effects of medicines for spinal muscular atrophy and Huntington's disease. - The funding is part of a $4.5 million NSW Government investment to reduce animal use in medical research and accelerate human-relevant therapeutic discovery.
- A novel implantable biobattery developed by researchers at University of Wollongong and Jilin University reduced tumor size from over 1,000 mm³ to just 4 mm³ in 14 days, achieving a 99.6% reduction. - The device works by releasing zinc and manganese ions that create a hostile microenvironment for cancer cells while stimulating the body's immune system to target and destroy tumors. - This breakthrough represents a potential paradigm shift toward drug-free cancer immunotherapy, offering targeted treatment with reduced side effects compared to conventional chemotherapy and radiation. - The research team is now advancing toward preclinical and clinical trials to translate this laboratory success into real-world patient treatments.
- University of Wollongong researchers received $500,000 from Australian Economic Accelerate Ignite Grants to develop ResectAssist™, a biodegradable implantable device for inoperable pancreatic cancer. - The device delivers high-dose chemotherapy directly into tumors using standard endoscopy techniques, aiming to convert non-resectable pancreatic tumors to resectable ones. - ResectAssist™-FOLFIRINOX delivers the FOLFIRINOX chemotherapy regimen locally to maximize anti-cancer efficacy while minimizing systemic side effects. - The collaboration between UOW and FivepHusion targets pancreatic cancer, which has survival rates under 10% and represents one of the most challenging cancers to treat.
